Current and future therapy in Alzheimer's disease

被引：99

作者：

van Marum, Robert J. ^{[1
]}

机构：

[1] Univ Utrecht, Med Ctr, Dept Geriatr, NL-3500 GA Utrecht, Netherlands

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2008年 / 22卷 / 03期

关键词：

alzheimer's disease; amyloid hypothesis; dementia; drug therapy;

D O I：

10.1111/j.1472-8206.2008.00578.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Dementia is increasingly being recognized as one of the most important medical problems in the elderly. As most pharmacological research within the field of dementia is focused on Alzheimer's dementia (AD), this review will focus on pharmacological interventions in AD. Most disease-modifying therapies are based on the amyloid hypothesis. In this hypothesis, the pathological accumulation of A beta in the brain leads to oxidative stress, neuronal destruction and finally the clinical syndrome of AD. Following this hypothesis, secondary prevention of AD can be made by: decreasing the production of A beta, stimulation of clearance of A beta formed or prevention of aggregation of A beta into amyloid plaques. First a short overview on current approved therapies for AD is given. The main part of the review will focus on potential disease-modifying therapies for AD that are currently being studied in phase I to phase III trials.

引用

页码：265 / 274

页数：10

共 68 条

[51] Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation [J].

Saito, T ;

Iwata, N ;

Tsubuki, S ;

Takaki, Y ;

Takano, J ;

Huang, SM ;

Suemoto, T ;

Higuchi, M ;

Saido, TC .

NATURE MEDICINE, 2005, 11 (04) :434-439

[52] Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ [J].

Sastre, M ;

Dewachter, I ;

Rossner, S ;

Bogdanovic, N ;

Rosen, E ;

Borghgraef, P ;

Evert, BO ;

Dumitrescu-Ozimek, L ;

Thal, DR ;

Landreth, G ;

Walter, J ;

Klockgether, T ;

van Leuven, F ;

Heneka, MT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (02) :443-448

[53] Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease [J].

Siemers, ER ;

Quinn, JF ;

Kaye, J ;

Farlow, MR ;

Porsteinsson, A ;

Tariot, P ;

Zoulnouni, P ;

Galvin, JE ;

Holtzman, DM ;

Knopman, DS ;

Satterwhite, J ;

Gonzales, C ;

Dean, RA ;

May, PC .

NEUROLOGY, 2006, 66 (04) :602-604

[54] Effect of baseline cognitive function and anti hypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) [J].

Skoog, I ;

Lithell, H ;

Hansson, L ;

Elmfeldt, D ;

Hofman, A ;

Olofsson, B ;

Trenkwalder, P ;

Zanchetti, A .

AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (08) :1052-1059

[55]

Solomon B, 2007, CURR OPIN INVEST DR, V8, P519

[56]

Strum JC, 2007, J ALZHEIMERS DIS, V11, P45

[57] Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial [J].

Tariot, PN ;

Farlow, MR ;

Grossberg, GT ;

Graham, SM ;

McDonald, S ;

Gergel, I .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (03) :317-324

[58]

TOBINICK E, 2006, MEDGENMED, V8, P24

[59] Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease - A meta-analysis [J].

Trinh, NH ;

Hoblyn, J ;

Mohanty, SU ;

Yaffe, K .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (02) :210-216

[60]

Tzourio C, 2003, ARCH INTERN MED, V163, P1069

← 1 2 3 4 5 6 7 →